A Randomized, Subject- and Investigator-blinded, Placebo-controlled Pharmacodynamic Study of Oral LIK066 in Overweight and Obese Women With Polycystic Ovary Syndrome
Phase of Trial: Phase II
Latest Information Update: 19 Sep 2017
At a glance
- Drugs LIK 066 (Primary)
- Indications Overweight; Polycystic ovary syndrome
- Focus Pharmacodynamics
- Sponsors Novartis Pharmaceuticals
- 24 Jul 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 Planned initiation date changed from 6 Jul 2017 to 29 Jun 2017.
- 17 May 2017 New trial record